vials

The PMO supports projects at their earliest proposal stages in order to help build a foundation upon which academics at Imperial can successfully lead high profile, EU funded initiatives

The PMO assists with a variety of consortium management activities including:

  • Identifying collaborators and building a well-rounded consortium consisting of academics, research organisations and industry partners – a must for any successful Horizon 2020 proposal.
  • Assessing and managing risk for the overall consortium.
  • Enhancing the impact of the project in line with funding calls and proposal guidelines.
  • Supporting the build-up for overall consortium budget and justifying the resources that are needed to undertake the project.
  • Coordinating project reporting activities and communications with the European Union Project Officer.
  • Putting together grant proposals and managing logistics including liaising with beneficiaries and uploading the proposal onto the European Commission’s single Common Grant Management System (SyGMa).

Case studies

3D-TuneIn

3D-games for TUNing and lEarnINg about hearing aids

3d TuneIn

3D Tune-In brings together relevant stakeholders from traditional gaming industries, academic institutes, a large European hearing aid manufacturer and hearing communities to produce digital games in the field of hearing aid technologies and hearing loss in children and older adults, addressing social inclusion, generating new markets and creating job opportunities.

Visit the website here.


3D Tune-in news

Audiology World News

3D Tune-In at the Imperial Festival

 

EAVI 2020

eavi2020

EAVI2020 is a 23 million euro initiative to accelerate the search for an effective HIV vaccine.

The EAVI2020 consortium, which is led by Imperial College London, brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA, pooling their knowledge and expertise to develop novel candidate vaccines that can be taken through to human trials within five years. EAVI2020 is funded with an EU-grant under the health program of Horizon 2020 for research and innovation.

To keep up to date with EAVI2020, you can visit the project's website, or follow their work on Twitter.


EAVI 2020 and HIV News

HIV scientists launch 23 million euro project to develop vaccine

HIV scientists launch £17 million project to develop vaccine

Charlie Sheen and the chase for an HIV vaccine

Is the end of AIDS in sight? 10 facts about HIV/AIDS ahead of World AIDS Day

EDEN 2020

EDEN 2020 logo

Due to an aging population and the spiralling cost of brain disease in Europe and beyond, EDEN2020 aims to develop the gold standard for one-stop diagnosis and minimally invasive treatment in neurosurgery. Supported by a clear business case, it will exploit the unique track record of leading research institutions and key industrial players in the field of surgical robotics to overcome the current technological barriers that stand in the way of real clinical impact. EDEN2020 will contribute to the wider clinical challenge of extending and enhancing the quality of life of cancer patients – with the ability to plan therapies around delicate tissue structures and with unparalleled delivery accuracy.

EDEN2020 will provide a step change in the modelling, planning and delivery of diagnostic sensors and therapies to the brain via flexible surgical access, with an initial focus on cancer therapy. It will engineer a family of steerable catheters for chronic disease management that can be robotically deployed and kept in situ for extended periods. The system will feature enhanced autonomy, surgeon cooperation, targeting proficiency and fault tolerance with a suite of technologies that are commensurate to the unique challenges of neurosurgery.

The €8.6mn project, which involves 8 industrial and academic partners from the UK, Italy, the Netherlands and Germany is coordinated by Imperial College’s Prof Ferdinando Rodriguez y Baena (Faculty of Engineering, Department of Mechanical Engineering). PMO provides consortium management and leads dissemination, communication and exploitation activities.

EUCLIDS

EUCLIDS: EU Childhood Life-threatening Infectious Diseases Study

EUCLIDS

EUCLIDS is a five-year, €12million project funded under the Health theme of the EU Commission’s Seventh Framework Programme (FP7), which supports European research and innovation.  The consortium is made up of 16 partners spread across three continents.

Using bacterial meningitis  and sepsis as prototypic models, EUCLIDS has undertaken a large scale genomic study (with a patient database now reaching just under 4000 patients) to identify genes biological pathways that may determine susceptibility and severity of life threatening bacterial infections, currently accounting for over a quarter of child deaths, globally.

The role of PMO

PMO’s role within EUCLIDS has focused on providing effective consortium management throughout the project, ensuring effective partner communication and timely implementation of deliverables. The dedicated PMO team also lead and facilitate dissemination and training activities, organise project events and manage the project website

"For me, one of the main benefits of PMO’s service so far is that a weight was taken from my shoulders in terms of coordinating the partners in order to successfully meet deliverable deadlines […] My time is precious and their input has helped preserve it for research and teaching duties" Prof Mike Levin, Department of Medicine and EUCLIDS Coordinator

 


EUCLIDS in the News

Major EU project will investigate genes that influence bacterial infections in children

MOCHA

MOCHAChildren’s health is important for Europe’s future. Today’s children are citizens, future workers, future parents and future carers. Children depend on good health services. But these are structured differently throughout the European Union, and there is little research into what works best. To help every child benefit from optimum health care, the MOCHA project will perform a systematic, scientific evaluation of the types of health care that exist.

The MOCHA scientific team are from 11 European countries, and will be joined by experts from Australia and the United States. We will use expertise from networks in child health, previous children’s health projects and knowledge from local agents in different European countries to build a picture of what type of health care for children exists in all 30 EU/EEA countries.

The disciplines encompassed by the project include medicine, nursing, economics, informatics, sociology and policy management. Emphasising prevention and on wellness, MOCHA aims to:

•  Categorise the models, and school health and adolescent services

•  Develop innovative measures of quality, outcome, cost and workforce of each and apply them using policy documents, routine statistics, and available electronic data sets

•  Assess effects on equality and on continuity of care with secondary care

•  Systematically obtain stakeholder views

•  Indicate optimal future patterns of electronic records and big data to optimise operation of the model(s).

Visit the website


MOCHA in the news

MOCHA kick off meeting held in London

International publicity for MOCHA

PERFORM

PERFORM is an €18 million collaborative project funded under the European Commission’s Horizon 2020 programme for research and innovation.

This five-year project will look at ways to reduce antibiotic misuse, through the development of improved tests used to distinguish
bacterial from viral infections. Currently, doctors have very limited capacity to reliably differentiate life-threatening bacterial infections from trivial viral illnesses in children. As a result, thousands of children worldwide undergo investigations such as lumbar punctures, x-rays and blood cultures, and are treated with broad spectrum antibiotics while waiting to rule out bacterial infection.

PerFORMProf. Michael Levin, lead PI and Professor of International Child Health at Imperial says “better tests to identify those children with life threatening infection amongst the infinitely more numerous children with viral infections are urgently needed if antibiotic use is to be reduced. We have exciting pilot data which shows that bacterial infection can be recognised by the patterns of genes and proteins switched on in each child’s blood during infection. PERFORM will apply sophisticated genomic and proteomic methods to study thousands of febrile children with the aim of identifying and developing a better test for bacterial infection than what is currently available.”

The consortium is led by Imperial College London, with partners in Oxford, Liverpool, Spain, Austria, Germany, the Netherlands, Greece, Slovenia, Latvia and Switzerland, along with two biotechnology companies (Micropathology Ltd in the UK and bioMérieux in France). PERFORM will study over 5 000 children presented to medical care with a fever, as well as collecting data on over 50 000 children suffering with a fever who present to hospitals across the partners' countries.

The project officially started in January 2016 and it’s “Kick-Off” meeting was held in London on 11-12 January.

More information will soon be available at http://www.perform2020.eu